# Richard S. Finn

Source: https://onco.cc/people/richard-finn/  
OnCo record `richard-finn` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led PALOMA-2, which made palbociclib a first-line breast cancer drug, and IMbrave150, which made immunotherapy the standard for liver cancer.

## Summary

Richard Finn was principal investigator of PALOMA-2, the trial that established palbociclib plus letrozole as first-line therapy for HR-positive advanced breast cancer and launched the CDK4/6 inhibitor class. He then led IMbrave150, which showed atezolizumab plus bevacizumab beat sorafenib in unresectable hepatocellular carcinoma, ending a decade of sorafenib as the only option. His current work covers next-generation CDK inhibitors and immunotherapy sequencing in liver cancer.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: breast; hcc; trialist
- Role: Professor of Medicine, UCLA Jonsson Comprehensive Cancer Center
- Specialisms: HR-positive breast cancer; CDK4/6 inhibitors; Hepatocellular carcinoma; Immunotherapy combinations

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Finn%20RS%5BAuthor%5D%20palbociclib%20OR%20atezolizumab

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- technologies: [CDK4/6 inhibitors](https://onco.cc/technologies/cdk46-inhibitor/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [CDK4/6](https://onco.cc/targets/cdk4-6/), [PD-L1](https://onco.cc/targets/pdl1/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Palbociclib](https://onco.cc/drugs/palbociclib/)
- institutions: [UCLA Jonsson Comprehensive Cancer Center](https://onco.cc/institutions/ucla-jonsson/)
- trials: [IMbrave150](https://onco.cc/trials/imbrave150/), [PALOMA-2](https://onco.cc/trials/paloma-2/)
- key papers: [IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer](https://onco.cc/key-papers/paper-imbrave150-nejm-2020/)

---
JSON: https://onco.cc/api/v1/entities/richard-finn.json